Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

Description

The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.

Conditions

Cerebral Aneurysm

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

Condition
Cerebral Aneurysm
Intervention / Treatment

-

Contacts and Locations

Miami

University of Miami, Miami, Florida, United States, 33136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Undergoing one of the following procedures at Jackson Memorial Hospital:
  • * Clipping of an unruptured cerebral artery aneurysm
  • * Endovascular treatment of unruptured cerebral aneurysms (including those receiving coiling)
  • 2. ≥ 18 years of age
  • 3. Willing and able to give informed consent
  • * Dissecting, traumatic, or mycotic brain aneurysm.
  • * Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.
  • * Women who are breastfeeding.
  • * Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol.
  • * Patients with known Human Immunodeficiency Virus (HIV) infection or other known immunodeficiency.
  • * Patient with renal or liver failure
  • * Interstitial pneumonitis
  • * History of lymphoma
  • * History of skin cancer
  • * Hypersensitivity to sirolimus
  • * Severe or unstable concomitant condition disease or chronic condition, which in the opinion of the investigator could affect assessment of the safety or efficacy of study intervention.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Miami,

Robert M Starke, M.D., PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

2026-11-01